technology PLATFORM

Accure’s iMES technology is a fully integrated digital diagnostic platform incorporating proprietary reagents, circuits and algorithms into one compact system.  By converting molecular data from biological fluid directly into electrical signals, Accure bypasses the limitations of existing optical diagnostic devices and significantly improves the speed and sensitivity of its tests. 

The technology was initially developed at the Harvard Medical School and Massachusetts General Hospital. It has been demonstrated in clinical studies to accurately detect cancer, transplant rejection, sepsis and food allergens. Accure’s next generation TiMES system is being developed to equip clinicians with a faster, less expensive, and fully automated solution for detecting and monitoring a range of diseases from a small quantity of biological fluid.

Selected Publications

1. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy.  Nat Med (2012)

2. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun (2015)

3. Integrated Magneto-Electrochemical Sensor for Exosome Analysis.  ACS Nano (2016)

4. Integrated Kidney Exosome Analysis (iKEA) For The Detection Of Kidney Transplant Rejection. ACS Nano (2017)

5. Integrated Magneto-Chemical Sensor For On-Site Food Allergen Detection. ACS Nano (2017)

6. Integrated Biosensor for Rapid and Point-Of-Care Sepsis Diagnosis. ACS Nano (2018)

7. Bioassay for monitoring the anti-aging effect of cord blood treatment. Theranostics (2019)

8. COVID-19 diagnostics in context. Sci Transl Med (2020)